Treatment with prophylactic oral anticoagulants and the risk of mortality in COVID-19 patients: a nationwide cohort study.

Sarah AltaraihiPeter Kamstrup Josefin EklöfNiklas Dyrby JohansenTor Biering-SorensenPradeesh SivapalanJens-Ulrik Stæhr Jensen

Published in: ERJ open research (2023)

In individuals with confirmed SARS-CoV-2, pre-existing treatment with OAC was not associated with prophylactic benefits in the prevention of hospital admission, ICU admissions or death. Prescription patterns should remain unchanged.

Keyphrases

sars cov
intensive care unit
healthcare
atrial fibrillation
risk factors
type diabetes
oral anticoagulants